Delio has raised a further USD8.3 million to enable financial institutions of all sizes to create greater investor access to alternative assets such as private equity, private debt, and real estate. The fintech, which digitises the private markets strategies of leading banks, wealth managers and other financial firms, received the backing from Octopus Ventures, one of Europe’s most active venture capital investors. Additional investment from early-backers Maven Capital Partners brings the total equity funding raised by Delio to USD15.5 million. The USD8.3 million investment will further enhance Delio’s international operations and lay the foundations of its non-conflicted private markets infrastructure.

CesiumAstroa developer of advanced aerospace communication systems, has closed an oversubscribed USD60 million Series B fundraising co-led by Airbus Ventures and Forever Ventures, with strategic participation from L3Harris Technologies (NYSE: LHX).

Public transport ticketing specialist Masabi has secured significant strategic growth investment from private equity firm Accel-KKR. Existing investors Shell and Smedvig Capital also participated in the round. The investment will fund the acceleration of product development and additional new deployments of Masabi’s Justride platform in North and South America, Europe and Asia-Pacific.

International law firm, RPC, has advised Danish private equity fund, Axcel on its acquisition of Carousel Logistics, a pan-European specialised provide of aftermarket and spare parts logistics. The RPC team, led by James Mee, David Wallis and Ben Magahy, worked alongside Danish law firm Accura, who led on Axcel’s concurrent acquisition of Danx, an in-night distributor of spare parts across the Nordics and Baltics.  SKW Schwarz provided German law advice and the transaction was completed on 28 February.   Axcel has acquired both firms to create a combined in-night logistics specialist offering end-to-end supply chain solution handling of time-sensitive spare

LaSalle Investment Management (LaSalle) has selected RealBlocks to cover the firm’s USD77 billion global real estate business.

Legends of Learning, Inc, creator of the nation’s leading educational game platform for K-12 students, has raised USD5 million in a seed round led by Konvoy Ventures, a venture capital fund dedicated to the games industry. Angel investors also participating in the round include James Park (Co-founder and CEO of Fitbit), Holly Liu (Co-founder at Kabam and former Visiting Partner at Y Combinator), Jeremy Liew (Partner at Lightspeed Venture Partners), and Kun Gao (Co-founder and Founding CEO of Crunchyroll).  Legends of Learning launched in 2017 as a solution to better engage students with academically rigorous coursework. Legends of Learning offers

Lightspeed Systems (Lightspeed), a specialist in learning safety and effectiveness, has secured a significant growth investment from Genstar Capital (Genstar). Genstar joins existing investor Madison Dearborn Partners (MDP), with the additional investment set to be used to help drive continued product innovation and position Lightspeed to accelerate its mission of keeping students safe and enabling equitable and effective learning.   Genstar and funds affiliated with Madison Dearborn will each have equal ownership stakes in Lightspeed while the founders and management team also retain a significant ownership position.

Sheridan Capital Partners (Sheridan) has completed the majority recapitalisation of SpendMend in partnership with management and Morgan Stanley Capital Partners (MSCP), the middle-market focused private equity team at Morgan Stanley Investment Management. Sheridan originally invested in SpendMend in January 2018 and enjoyed four successful years working closely with the founders. Co-founder and CEO Dan Geelhoed and co-founder and President Rob Heminger will continue to lead the business, while Sheridan has retained a minority ownership stake and board seat.   SpendMend is a provider of tech-enabled solutions to optimise the cost cycle for the US healthcare industry, and serves more than

British Patient Capital has invested in Epsilogen, a London-based developer of novel therapeutic antibodies to treat cancer, as part of a GBP30.75m Series B funding round. The investment has been made via Future Fund: Breakthrough, a GBP375 million programme where BPC co-invests with private sector investors in innovative, R&D-intensive UK companies. Based at the London BioScience Innovation Centre, Epsilogen is working with immunoglobulin E (IgE) antibodies to develop new therapeutic treatments for solid tumours.